Cancer Immunotherapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cancer Immunotherapy Market is Segmented by Therapy Type (Monoclonal Antibodies, Cancer Vaccines, Immunomodulators, Immune Check Point Inhibitors, and Other Therapy Types), Application (Prostate Cancer, Breast Cancer, Skin Cancer, Lung Cancer, and Other Applications), End Users (Hospitals and Clinics, Cancer Research Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Cancer Therapy Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 9.1 %
Cancer Therapy Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cancer immunotherapy market is projected to register a CAGR of 9.1% during the forecast period of 2022-2027.

Owing to the COVID-19 pandemic, the market has been negatively impacted due to the shortage and irregular supply of cancer immunotherapy products. This might allow local manufacturers to increase their presence in the market. Additionally, some biopharmaceutical companies, such as Merck & Co. Inc. and Eli Lilly and Company, announced clinical trial delays. For instance, the data from ClinicalTrials.gov showed that more than 200 interventional oncology studies were suspended in March and April 2020 as a result of the COVID-19 pandemic. Also, 60% of institutions in the United States and 86% in Europe are enrolling new patients at a lower rate. Globally, companies are focusing on developing drugs or vaccines, especially immunotherapy-based drugs for COVID-19, because immunotherapy is highly effective since it stimulates patients’ immune systems. This is expected to impact the market growth for a short period.

Certain factors driving the market growth include rising R&D activities, increasing effectivity and accuracy of newer therapies, rising adoption of target therapy over traditional therapy, and the growing prevalence of cancer. The increasing incidence of cancer is a major factor in the growth of the cancer immunotherapy market. According to the National Clinical Trials (NCT) Registry, as of September 8, 2020, there were more than 1,000 ongoing clinical trials globally across different phases of development for the treatment of cancer with immune-based therapies. Moreover, as these therapies are in development, if trials show positive outcomes shortly, new effective immuno-therapies can be expected for cancer.

Cancer immunotherapy plays a vital role in the maintenance of the immune system since it targets the infectious agents that may cause cancer through the production of antibodies. Cancer immunotherapy is considered to be new therapy, but it has shown great potential over the past few years. Also, with the huge burden of cancer cases and side effects of the present therapies, the market is expected to record a high growth rate during the forecast period.

Therefore, the presence of immunotherapy drugs like Keytruda has successfully extended life expectancy for some mesothelioma patients in clinical trials, which are expected to have a positive impact on the market. Thus, increasing efficacy and accuracy of the newer therapies, along with lesser side effects compared to traditional chemotherapy, are expected to drive the market growth over the forecast period.

Scope of the Report

As per the scope of the report, immunotherapy is a treatment that uses certain parts of a person’s immune system to fight diseases, such as cancer. This can be done either by stimulating one’s own immune system to work better to attack cancer cells or by giving one immune system components, such as artificial immune system proteins. Cancer immunotherapy boosts the body's natural defenses to fight against cancer. It uses substances made by the body or in a laboratory to improve the immune system to find and destroy cancer cells. The cancer immunotherapy market is segmented by therapy type (monoclonal antibodies, cancer vaccines, immunomodulators, immune checkpoint inhibitors, and other therapy types), application (prostate cancer, breast cancer, skin cancer, lung cancer, and other applications), end users (hospitals and clinics, cancer research centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Therapy Type
Monoclonal Antibodies
Cancer Vaccines
Immunomodulators
Immune Check Point Inhibitors
Other Therapy Types
By Application
Prostate Cancer
Breast Cancer
Skin Cancer
Lung Cancer
Other Applications
By End Users
Hospitals and Clinics
Cancer Research Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Breast Cancer Segment Expected to Hold a Major Share in the Cancer Immunotherapy Market

Breast cancer is cancer that develops in the breast cells. The signs of breast cancer include a lump in the breast, a change in breast shape, dimpling of the skin, a newly inverted nipple, or a red or scaly patch of skin.

The COVID-19 pandemic affected many market aspects, including screening, diagnosis, treatment, and follow-up care for breast cancer. The people diagnosed with breast cancer and people at high risk for breast cancer found themselves in a uniquely difficult position since the pandemic began. A retrospective multicentric study by Li J. et al. collected data on 8397 breast cancer patients from 97 Chinese cancer centers. Therefore, the Hubei province recorded the lowest incidence of early breast cancer (5.3%) in comparison to the other provinces (15.3%). Surgical procedures also decreased dramatically from 16.4% (December 2019) to 2.6% (February 2020), and there was also a delay in timelines from surgery to adjuvant therapy. Therefore, due to the shutdowns and increasing social distancing, there were a large number of delays in breast cancer surgeries that impacted the overall market negatively. Also, some breast cancer treatments, including chemotherapy, targeted therapies, and immunotherapy, weaken the immune system and possibly cause lung problems.

According to the Center for Disease Control and Prevention (CDC), breast cancer is the most common cancer among women. There is a rising number of breast cancer cases across the globe, which is driving the overall growth of the market. Thus, the increasing need for effective and lasting breast cancer treatment is necessary.

The increasing R&D and awareness about breast cancer are expected to boost the overall growth of the market. For instance, the Breast Cancer Research Foundation (BCRF) is a non-profit organization providing critical funding for cancer research across the globe to fuel advances in tumor biology, genetics, prevention, treatment, metastasis, and survivorship. Also, breastcancer.org provides the most reliable, complete, and updated information about breast cancer to create awareness among patients.

Cancer Therapy Market - Incidence of New Cancer Cases, By Cancer Type, Global, 2020

North America Expected to Continue Market Dominance over the Forecast Period

The major factors driving the market’s growth in North America are developed healthcare infrastructure and increased government initiatives, which offer lucrative reimbursement policies.

The COVID-19 pandemic affected the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Companies such as Pfizer, Eli Lilly and Company, and Bristol-Myers Squibb halted clinical trials due to the COVID-19 pandemic. Hence, it negatively impacts the market studied due to the shortage and irregular supply of cancer immunotherapy products.

According to the estimates of the GLOBOCAN in 2020, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the United States.

The Canadian Cancer Society (CCS) estimated that in 2020, approximately 29,800 Canadians were diagnosed with lung cancer, which amounted to 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates a huge potential market demand for cancer immunotherapy. Owing to the increasing burden of various types of cancer, the market studied is expected to grow.

The market players are also focusing on launching new products in the market. Furthermore, various organizations are increasing awareness among consumers regarding cancer. Therefore, with the increasing cancer burden and the rising R&D in the field of cancer, the market is expected to experience lucrative growth during the forecast period.

Cancer Therapy Market - Growth Rate by Region

Competitive Landscape

The cancer immunotherapy market is highly competitive and consists of a few major players. Companies like Amgen Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman La Roche, Merck and Co., Novartis, and OSE Immunotherapeutics, among others, hold a substantial share in the cancer immunotherapy market. The market players have also been significantly investing in R&D for cancer therapy, which along with the increasing product approvals, are further driving the market growth.

Recent Developments

· In May 2021, the US FDA approved Amgen’s LUMAKRAS (Sotorasib) for treatment of patients with KRAS G12C, which involves mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). LUMAKRAS is the first and only targeted treatment for NSCLC.

· In May 2021, Astellas Pharma announced the approval of the XTANDI therapy (enzalutamide) by the European Commission. XTANDI is the only available approved oral treatment for three kinds of prostate cancer, including non-metastatic, metastatic hormone sensitive, and metastatic castration resistant.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising R&D Activities

      2. 4.2.2 Increasing Effectivity and Accuracy Of Newer Therapies

      3. 4.2.3 Growing Prevalence of Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Coupled with Expensive Development

      2. 4.3.2 Stringent Regulatory Factors

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy Type

      1. 5.1.1 Monoclonal Antibodies

      2. 5.1.2 Cancer Vaccines

      3. 5.1.3 Immunomodulators

      4. 5.1.4 Immune Check Point Inhibitors

      5. 5.1.5 Other Therapy Types

    2. 5.2 By Application

      1. 5.2.1 Prostate Cancer

      2. 5.2.2 Breast Cancer

      3. 5.2.3 Skin Cancer

      4. 5.2.4 Lung Cancer

      5. 5.2.5 Other Applications

    3. 5.3 By End Users

      1. 5.3.1 Hospitals and Clinics

      2. 5.3.2 Cancer Research Centers

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Astellas Pharma Inc.

      3. 6.1.3 AstraZeneca PLC

      4. 6.1.4 Bayer AG

      5. 6.1.5 Bristol-Myers Squibb

      6. 6.1.6 Eli Lilly and Company

      7. 6.1.7 F. Hoffman La Roche Ltd

      8. 6.1.8 Merck and Co. Inc.

      9. 6.1.9 Novartis AG

      10. 6.1.10 OSE Immunotherapeutics

      11. 6.1.11 Seattle Genetics Inc.

      12. 6.1.12 Pfizer Inc.

      13. 6.1.13 Gilead Sciences

      14. 6.1.14 GlaxoSmithKline PLC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cancer Immunotherapy Market market is studied from 2019 - 2027.

The Cancer Immunotherapy Market is growing at a CAGR of 9.1% over the next 5 years.

The Cancer Immunotherapy Market is valued at 85 Billion USD in 2019.

The Cancer Immunotherapy Market is valued at 153 Billion USD in 2027.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Amgen Inc., Astellas Pharma, Inc., AstraZeneca PLC , Merck and Co Inc., OSE Immunotherapeutics are the major companies operating in Cancer Immunotherapy Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!